Search
Aurinia Pharmaceuticals Inc
AUPHAdd to Watchlist
15.800USD
-1.170-6.89%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
2.09BMarket Cap
7.09P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-6.89%
5 Days
-15.15%
1 Month
+3.20%
6 Months
-0.94%
Year to Date
-0.94%
1 Year
+111.23%
Key Figures
16.980Open
17.120High
2.04MVolume
7.09P/E TTM
12.95P/E Dynamic
--Dividend TTM
1.54%Turnover Ratio
16.970Prev. Close
15.775Low
23.33MTurnover
363.47P/E Static
3.60P/B
0.00%Div Yield TTM
48.54%ROA
16.88052wk High
0.63Volume Ratio
5.75MNet Profit
132.32MShares
2.2289EPS TTM
1.43Beta
64.98%ROE
7.28552wk Low
7.93%Amplitude
91.63%Gross Margin
2.09BMarket Cap
3.85Reward/Risk
2.67%Risk Rate
TradingKey Stock Score of Aurinia Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
Aurinia Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aurinia Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Aurinia Pharmaceuticals Inc Highlights
StrengthsRisks
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 61.27% year-on-year.
Fairly Valued
The company’s latest PE is 7.09, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 74.86M shares, decreasing 0.56% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 79.79K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.30.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
17.000
Target Price
+0.18%
Upside Space
Aurinia Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aurinia Pharmaceuticals Inc Info
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Ticker SymbolAUPH
CompanyAurinia Pharmaceuticals Inc
CEOGreenleaf (Peter S)
Websitehttps://www.auriniapharma.com
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52358.200
+103.900 (+0.20%)
29957.400
+158.100 (+0.53%)
7499.800
+24.300 (+0.33%)
14988.000
-367.000 (-2.39%)
69819.000
+334.000 (+0.48%)
6298.200
+22.800 (+0.36%)
67.661
-0.307 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.170
+24.400 (+0.60%)
FAQs
What is the current price of Aurinia Pharmaceuticals Inc (AUPH)?
The current price of Aurinia Pharmaceuticals Inc (AUPH) is 15.80.
What is the symbol of Aurinia Pharmaceuticals Inc?
The ticker symbol of Aurinia Pharmaceuticals Inc is AUPH.
What is the 52-week high of Aurinia Pharmaceuticals Inc?
The 52-week high of Aurinia Pharmaceuticals Inc is 16.88.
What is the 52-week low of Aurinia Pharmaceuticals Inc?
The 52-week low of Aurinia Pharmaceuticals Inc is 7.29.
What is the market capitalization of Aurinia Pharmaceuticals Inc?
The market capitalization of Aurinia Pharmaceuticals Inc is 2.09B.
Is Aurinia Pharmaceuticals Inc (AUPH) currently rated as Buy, Hold, or Sell?
According to analysts, Aurinia Pharmaceuticals Inc (AUPH) has an overall rating of Buy, with a price target of 17.00.
What is the Earnings Per Share (EPS TTM) of Aurinia Pharmaceuticals Inc (AUPH)?
The Earnings Per Share (EPS TTM) of Aurinia Pharmaceuticals Inc (AUPH) is 2.14.